Qiu Jin, Han Li-Ying, Xing Hong-Yun, Gao Kun-Li, Bian Tie-Rong
Department of General Medicine, Luzhou People's Hospital, Luzhou 646000, Sichuan Province, China.
Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Feb;31(1):241-246. doi: 10.19746/j.cnki.issn.1009-2137.2023.01.038.
To explore the effect of recombinant human thrombopoietin (rhTPO) on hematopoietic reconstruction in allogeneic hematopoietic stem cell transplantation (allo-HSCT) model.
The C57BL/6 mice were employed as the donors, and BALB/c mice as recipients. The bone marrow mononuclear cells of the donor mice were extracted and pretreated, which then were injected with 5×10 per mouse through the tail vein of the recipient to establish an allo-HSCT model. The implantation of hematopoietic stem cells in the recipient mice was detected by flow cytometry on the 28 day after transplantation. Next, the successfully modeled recipient mice were randomly divided into experimental group and control group. The rhTPO was injected into mice in the experimental group on the first day after transplantation, while the saline was injected into mice in the control group. Both groups were injected for 14 consecutive days. The peripheral blood and bone marrow hematopoiesis of the two groups were observed on day 1, 3, 7, 14, and 21 after transplantation.
The expression rate of H-2K in the bone marrow of recipient mice was 43.85% (>20%) on the 28 day after transplantation, which indicated that the recipient mice were successfully chimerized. Meanwhile, counts of PLTs on the day 3, 7, 14, and 21 after transplantation in the experimental group were higher than those in the control group with statistical significances (<0.05). In addition, hematopoietic function of bone marrow was suppressed in both groups on day 1, 3 and 7 after transplantation, but hematopoietic bone marrow hyperplasia was better in the experimental group than in the control group. On day 14 and 21 after transplantation, the hematopoietic function of bone marrow in the two groups was recovered, and the experimental group showed more obvious than the control group.
rhTPO can effectively stimulate the production of PLTs and facilitate the recovery of white blood cells and hemoglobin after allo-HSCT, and promote hematopoietic recovery and reconstitution of bone marrow.
探讨重组人血小板生成素（rhTPO）对异基因造血干细胞移植（allo-HSCT）模型中造血重建的影响。
以C57BL/6小鼠为供体，BALB/c小鼠为受体。提取供体小鼠骨髓单个核细胞并进行预处理，然后通过受体小鼠尾静脉以每只小鼠5×10个细胞的剂量注射，建立allo-HSCT模型。移植后第28天通过流式细胞术检测受体小鼠造血干细胞的植入情况。接下来，将成功建模的受体小鼠随机分为实验组和对照组。实验组小鼠在移植后第1天注射rhTPO，对照组小鼠注射生理盐水。两组均连续注射14天。观察移植后第1、3、7、14和21天两组的外周血和骨髓造血情况。
移植后第28天受体小鼠骨髓中H-2K的表达率为43.85%（>20%），表明受体小鼠成功嵌合。同时，实验组移植后第3、7、14和21天的血小板计数高于对照组，差异有统计学意义（<0.05）。此外，移植后第1、3和7天两组骨髓造血功能均受到抑制，但实验组骨髓造血增生情况优于对照组。移植后第14和21天，两组骨髓造血功能均恢复，且实验组比对照组更明显。
rhTPO能有效刺激血小板生成，促进allo-HSCT后白细胞和血红蛋白的恢复，促进骨髓造血恢复和重建。
